Anti-Tumor Drugs Market by Indications, Route of Administration, Drug Class, Distribution Channels, End User - Global Forecast 2025-2030- Product Image

Sale

Anti-Tumor Drugs Market by Indications, Route of Administration, Drug Class, Distribution Channels, End User - Global Forecast 2025-2030

Report
197 Pages
October 2024
Region: Global
360iResearch™
ID: 5367839

UP TO €681EUR$697USD£568GBP OFF until Dec 31^st 2024

The Anti-Tumor Drugs Market grew from USD 34.89 billion in 2023 to USD 39.14 billion in 2024. It is expected to continue growing at a CAGR of 12.24%, reaching USD 78.35 billion by 2030.

The anti-tumor drugs market encompasses the development, production, and distribution of pharmaceuticals aimed at inhibiting or halting tumor growth, playing a crucial role in oncology treatments. These drugs include chemotherapy agents, targeted therapies, immunotherapies, and hormone therapies, serving a broad spectrum of cancers. Driven by rising cancer prevalence, the application of these drugs extends across hospitals, clinics, and research institutes. The growing diversification of treatment protocols highlights the necessity for innovative therapies and personalized medicine approaches. Key end-users include medical professionals, hospital pharmacies, and patients undergoing cancer treatment, with the increasing adoption of combination therapies expanding the market's reach.

Market insights suggest robust growth fueled by advancements in biotechnology and genomic research, enabling more targeted and effective drugs with potentially fewer side effects. Rising healthcare expenditure and supportive government policies further amplify market expansion. Emerging opportunities materialize from the integration of AI and machine learning to expedite drug discovery, alongside the burgeoning demand for biosimilars in cost-sensitive markets. Companies should capitalize on strategic partnerships with biotech firms and academic institutions to accelerate R&D processes, tapping into these technologies for sustained growth.

However, challenges such as high R&D costs, stringent regulatory approvals, and the complex nature of biologic drug manufacturing pose significant barriers. The market also faces pricing pressures due to increasing competition and the demand for cost-effective cancer treatments. Navigating these limitations requires a focus on enhancing manufacturing efficiency and ensuring a diverse pipeline of novel therapeutics.

Innovation avenues lie in the formulation of precision medicine, exploring synergistic drug combinations, and advancing immunotherapy techniques. Conducting comprehensive market analysis to identify emerging trends and unmet needs will be key for businesses aiming to capture new market segments. Overall, the anti-tumor drugs market is dynamic and resilient, with substantial potential for growth driven by scientific advancements and the continual need to address cancer's evolving landscape.

Understanding Market Dynamics in the Anti-Tumor Drugs Market

The Anti-Tumor Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Rise in incidence of cancer with the surge in the geriatric population
- Growing awareness regarding early diagnosis and treatment for the cancer
- Increase in expenditures on healthcare by government
Market Restraints
- High cost of anticancer drugs and low survival rate
Market Opportunities
- Availability of pipelined drugs and upsurge in demand for personalized medicines for the tumor treatment
- Recent innovations in anticancer therapies
Market Challenges
- Unfavorable outcomes associated with the use of cancer drugs

Exploring Porter’s Five Forces for the Anti-Tumor Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Anti-Tumor Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Anti-Tumor Drugs Market

External macro-environmental factors deeply influence the performance of the Anti-Tumor Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Anti-Tumor Drugs Market

The Anti-Tumor Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Anti-Tumor Drugs Market

The Anti-Tumor Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Anti-Tumor Drugs Market

The Anti-Tumor Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Tumor Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cybrexa Therapeutics, Dr. Reddy’s Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Getwell Oncology, GLS Pharma Pvt. Ltd., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., PharmaMar, Sanofi SA, Taiho Oncology, Inc, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Anti-Tumor Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Indications
- Breast Cancer
- Leukemia
- Lung Cancer
- Melanoma
- Prostate Cancer
Route of Administration
- Intra-muscular
- Intraperitoneal
- Intravenous
- Intraventricular or Intrathecal
- Intravesicular
- Oral
- Subcutaneous
- Topical
Drug Class
- Cytotoxics
- Hormonal Therapy
- Targeted Therapy
  - Monoclonal Antibodies
  - Small Molecule Inhibitors
Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
End User
- Clinics
- Hospitals
- Specialty Centers

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in incidence of cancer with the surge in the geriatric population
5.1.1.2. Growing awareness regarding early diagnosis and treatment for the cancer
5.1.1.3. Increase in expenditures on healthcare by government
5.1.2. Restraints
5.1.2.1. High cost of anticancer drugs and low survival rate
5.1.3. Opportunities
5.1.3.1. Availability of pipelined drugs and upsurge in demand for personalized medicines for the tumor treatment
5.1.3.2. Recent innovations in anticancer therapies
5.1.4. Challenges
5.1.4.1. Unfavorable outcomes associated with the use of cancer drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Anti-Tumor Drugs Market, by Indications

6.1. Introduction
6.2. Breast Cancer
6.3. Leukemia
6.4. Lung Cancer
6.5. Melanoma
6.6. Prostate Cancer

7. Anti-Tumor Drugs Market, by Route of Administration

7.1. Introduction
7.2. Intra-muscular
7.3. Intraperitoneal
7.4. Intravenous
7.5. Intraventricular or Intrathecal
7.6. Intravesicular
7.7. Oral
7.8. Subcutaneous
7.9. Topical

8. Anti-Tumor Drugs Market, by Drug Class

8.1. Introduction
8.2. Cytotoxics
8.3. Hormonal Therapy
8.4. Targeted Therapy
8.4.1. Monoclonal Antibodies
8.4.2. Small Molecule Inhibitors

9. Anti-Tumor Drugs Market, by Distribution Channels

9.1. Introduction
9.2. Hospital Pharmacies
9.3. Retail Pharmacies

10. Anti-Tumor Drugs Market, by End User

10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Specialty Centers

11. Americas Anti-Tumor Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Anti-Tumor Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Anti-Tumor Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. ANTI-TUMOR DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTI-TUMOR DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ANTI-TUMOR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. ANTI-TUMOR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. ANTI-TUMOR DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTI-TUMOR DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRA-MUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENTRICULAR OR INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVESICULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CYTOTOXICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 56. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 59. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 60. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 65. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 66. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 88. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 91. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 92. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 94. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 97. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 98. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 106. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 109. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 110. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 115. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 116. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 121. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 122. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 127. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 128. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 133. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 134. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 139. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 140. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 142. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 145. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 146. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 151. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 152. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 160. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 161. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 163. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 164. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 165. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 167. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 170. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 171. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 173. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 176. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 177. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 182. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 183. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 185. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 188. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 189. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 194. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 195. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 197. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 200. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 201. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 215. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 217. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 218. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 219. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 221. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 224. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 225. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 227. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 230. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 231. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 251. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 253. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 254. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 255. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 269. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 271. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 272. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 273. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 284. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. ANTI-TUMOR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 287. ANTI-TUMOR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Anti-Tumor Drugs Market, which are profiled in this report, include:

AbbVie Inc.
Amgen inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
Biogen Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Cybrexa Therapeutics
Dr. Reddy’s Laboratories Ltd.
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Genentech, Inc.
Getwell Oncology
GLS Pharma Pvt. Ltd.
Merck & Co., Inc.
Novartis AG
Otsuka Pharmaceutical Co., Ltd
Pfizer Inc.
PharmaMar
Sanofi SA
Taiho Oncology, Inc
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	197
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 39.14 Billion
Forecasted Market Value ( USD ) by 2030	$ 78.35 Billion
Compound Annual Growth Rate	12.2%
Regions Covered	Global
No. of Companies Mentioned	26

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3464EUR$3,545USD£2,892GBP €3849EUR$3,939USD£3,213GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6128EUR$6,272USD£5,116GBP €6809EUR$6,969USD£5,684GBP

Understanding Market Dynamics in the Anti-Tumor Drugs Market

Exploring Porter’s Five Forces for the Anti-Tumor Drugs Market

Applying PESTLE Analysis to the Anti-Tumor Drugs Market

Analyzing Market Share in the Anti-Tumor Drugs Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Anti-Tumor Drugs Market

Strategic Recommendations for Success in the Anti-Tumor Drugs Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Desmoid Tumors Market by Drug Type, Treatment Type, End User, Age Group, Tumor Location - Global Forecast 2025-2030

Anti-Vascular Endothelial Growth Factor Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F

Japan Chemotherapy Market, By Region, Competition, Forecast & Opportunities, 2020-2030F

Gastrointestinal Stromal Tumors - Pipeline Insight, 2024

Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024